Evidence map›Paper›PMID 30032410›Full record

Trial reportInvestigational new drugs2019

Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects.

Zhi-Yi Zhang, Jing Wang, Vikram Kansra, Xiaodong Wang

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Investigational new drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Zhi-Yi ZhangTESARO, 1000 Winter Street, Waltham, MA, 02451, USA.
Jing WangTESARO, 1000 Winter Street, Waltham, MA, 02451, USA.
Vikram KansraTESARO, 1000 Winter Street, Waltham, MA, 02451, USA.
Xiaodong WangTESARO, 1000 Winter Street, Waltham, MA, 02451, USA. xddwang@gmail.com.
Tesaro (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rolapitant is a neurokinin-1 receptor antagonist that is approved in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting (CINV) associated with initial and repeat courses of emetogenic cancer chemotherapy, including but not limited to highly emetogenic chemotherapy. Here, we assessed the absorption, metabolism, and excretion of

Indexed as

AdultAntiemeticsHealthy VolunteersHumansMaleMiddle AgedNauseaNeurokinin-1 Receptor AntagonistsSpiro CompoundsTissue DistributionVomitingAntiemeticsNeurokinin-1 Receptor AntagonistsrolapitantSpiro CompoundsADMEMass balanceMetabolitesRadiolabeledRolapitant

Identifiers

PMID30032410
OpenAlexW2884078845

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.